Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTU NASDAQ:BLRX NASDAQ:MREO NASDAQ:TIL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$2.11-4.1%$2.50$1.58▼$11.99$52.64M0.92114,711 shs153,406 shsBLRXBioLineRx$3.37+6.6%$2.61$2.15▼$7.77$13.75M1.42103,166 shs96,345 shsMREOMereo BioPharma Group$0.33-1.5%$0.30$0.20▼$3.05$53.26M0.242.88 million shs57.54 million shsTILInstil Bio$8.14+0.2%$8.24$5.67▼$42.79$55.07M1.9433,168 shs12,215 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-7.56%-8.33%-25.93%-45.81%-78.70%BLRXBioLineRx+3.27%+20.15%+39.82%+14.49%-13.66%MREOMereo BioPharma Group+19.91%+40.21%+15.07%-15.30%-85.10%TILInstil Bio-0.73%+1.25%+0.74%-5.03%-61.37%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$2.11-4.1%$2.50$1.58▼$11.99$52.64M0.92114,711 shs153,406 shsBLRXBioLineRx$3.37+6.6%$2.61$2.15▼$7.77$13.75M1.42103,166 shs96,345 shsMREOMereo BioPharma Group$0.33-1.5%$0.30$0.20▼$3.05$53.26M0.242.88 million shs57.54 million shsTILInstil Bio$8.14+0.2%$8.24$5.67▼$42.79$55.07M1.9433,168 shs12,215 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics-7.56%-8.33%-25.93%-45.81%-78.70%BLRXBioLineRx+3.27%+20.15%+39.82%+14.49%-13.66%MREOMereo BioPharma Group+19.91%+40.21%+15.07%-15.30%-85.10%TILInstil Bio-0.73%+1.25%+0.74%-5.03%-61.37%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 2.33Hold$17.50729.38% UpsideBLRXBioLineRx 2.67Moderate BuyN/AN/AMREOMereo BioPharma Group 2.13Hold$3.25888.74% UpsideTILInstil Bio 1.75Reduce$66.00710.81% UpsideCurrent Analyst Ratings BreakdownLatest BLRX, TIL, MREO, and ACTU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.005/12/2026MREOMereo BioPharma Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/12/2026MREOMereo BioPharma Group BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1.004/22/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.004/20/2026BLRXBioLineRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/13/2026ACTUActuate Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.003/27/2026ACTUActuate Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026TILInstil Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/23/2026MREOMereo BioPharma Group JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral3/19/2026MREOMereo BioPharma Group Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/A$0.16 per shareN/ABLRXBioLineRx$1.18M12.43N/AN/A$5.36 per share0.63MREOMereo BioPharma Group$500K104.93N/AN/A$0.21 per share1.57TILInstil BioN/AN/AN/AN/A$16.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$22.23M-$0.97N/AN/AN/AN/A-430.93%-180.86%N/ABLRXBioLineRx-$1.17M-$0.17N/AN/AN/A-99.58%-5.61%-2.81%N/AMREOMereo BioPharma Group-$41.88M-$0.05N/A32.87N/AN/A-81.28%-70.45%8/11/2026 (Estimated)TILInstil Bio-$71.37M-$7.08N/AN/AN/AN/A-39.76%-22.38%8/12/2026 (Estimated)Latest BLRX, TIL, MREO, and ACTU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q1 2026BLRXBioLineRx-$1.04-$0.36+$0.68-$0.36$0.34 million$0.48 million5/15/2026Q1 2026TILInstil Bio-$0.62-$0.62N/A-$0.62N/AN/A5/14/2026Q1 2026ACTUActuate Therapeutics-$0.23-$0.24-$0.01-$0.24N/AN/A5/12/2026Q1 2026MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.05$11.67 millionN/A3/27/2026Q4 2025TILInstil Bio-$2.31-$1.21+$1.10-$1.21$1.90 millionN/A3/26/2026Q4 2025ACTUActuate Therapeutics-$0.24-$0.18+$0.06-$0.18N/AN/A3/24/2026Q4 2025BLRXBioLineRx-$0.50-$0.34+$0.16N/A$0.49 million$0.19 million3/20/2026Q4 2025MREOMereo BioPharma Group-$0.01-$0.01N/A-$0.05$5.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ABLRXBioLineRxN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.801.80BLRXBioLineRx0.191.951.78MREOMereo BioPharma GroupN/A6.486.48TILInstil Bio0.7739.8739.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ABLRXBioLineRx1.56%MREOMereo BioPharma Group62.83%TILInstil Bio60.56%Insider OwnershipCompanyInsider OwnershipACTUActuate Therapeutics57.98%BLRXBioLineRx1.10%MREOMereo BioPharma Group6.50%TILInstil Bio47.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1023.93 million10.05 millionN/ABLRXBioLineRx404.35 million4.30 millionOptionableMREOMereo BioPharma Group40159.62 million149.24 millionOptionableTILInstil Bio4106.78 million3.59 millionNo DataBLRX, TIL, MREO, and ACTU HeadlinesRecent News About These CompaniesInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 15, 2026 | globenewswire.comInstil Bio (TIL) Price Target Increased by 24.53% to 67.32April 9, 2026 | msn.comInstil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateMarch 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILFebruary 12, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILFebruary 3, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 29, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio,January 27, 2026 | bakersfield.comBINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 27, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 22, 2026 | prnewswire.comTIL ALERT: Ongoing Investigation Into Instil Bio, Inc. - Contact Levi & KorsinskyJanuary 20, 2026 | newsfilecorp.comNINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 20, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 15, 2026 | prnewswire.comInstil Bio (TIL) Price Target Decreased by 45.17% to 53.55January 14, 2026 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 13, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TILJanuary 8, 2026 | prnewswire.comHC Wainwright & Co. downgrades Instil Bio (TIL)January 8, 2026 | msn.comArrowhead showcases early obesity data; Instil bails on PD-1/VEGF drugJanuary 7, 2026 | biopharmadive.comBInstil Bio shares slide on discontinuation of lead clinical programsJanuary 6, 2026 | proactiveinvestors.comInstil Bio Pulls Plug On Lead Drug DevelopmentJanuary 6, 2026 | benzinga.comInstil Bio stock falls after subsidiary discontinues AXN-2510 developmentJanuary 6, 2026 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMeta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand NowBy Leo Miller | May 11, 20263 Rare Earth Stocks That Win No Matter What China Does NextBy Bridget Bennett | May 24, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026Is Everspin Technologies the Next AI Edge Breakout?By Thomas Hughes | May 18, 2026These 3 AI Stocks Just Crushed Earnings: Still Time To Buy?By Dan Schmidt | May 2, 2026BLRX, TIL, MREO, and ACTU Company DescriptionsActuate Therapeutics NASDAQ:ACTU$2.11 -0.09 (-4.09%) Closing price 04:00 PM EasternExtended Trading$2.11 0.00 (0.00%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.BioLineRx NASDAQ:BLRX$3.37 +0.21 (+6.65%) Closing price 04:00 PM EasternExtended Trading$3.34 -0.04 (-1.04%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Mereo BioPharma Group NASDAQ:MREO$0.33 -0.01 (-1.50%) Closing price 04:00 PM EasternExtended Trading$0.32 0.00 (-1.13%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Instil Bio NASDAQ:TIL$8.14 +0.02 (+0.25%) Closing price 04:00 PM EasternExtended Trading$8.22 +0.08 (+0.93%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
